Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

References

• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53
   PubMed Web of Science ®Google Scholar
• Anon. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28:S37–S42
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977–86
   Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002;287:360–72
   PubMed Web of Science ®Google Scholar
• Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003;3:365–72
   PubMedGoogle Scholar
• Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929–40
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Revel L, Castaner J. P32/98: antidiabetic dipeptidylpeptidase IV inhibitor. Drugs Future 2001;26: 859–64
   Google Scholar
• Villhauer EB, Coppola GM, Hughes TE. DPP-IV inhibition and therapeutic potential. Annu Rep Med Chem 2001;36: 191–200
   Web of Science ®Google Scholar
• Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741–50
   PubMed Web of Science ®Google Scholar
• Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002;51: 943–50
   PubMed Web of Science ®Google Scholar
• Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888–94
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28: 1936–40
   PubMed Web of Science ®Google Scholar
• Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146: 717–27
   Google Scholar
• Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141–51
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther 2005;78:675–88
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55–72
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydro-chloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991–3026
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. New Engl J Med 1996;334:574–9
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;doi:10.1210/jc.2006–1009
   Google Scholar
• Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24: 489–94
   PubMed Web of Science ®Google Scholar
• Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002;291: 1302–8
   PubMed Web of Science ®Google Scholar
• Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004;324:92–7
   PubMedGoogle Scholar
• Wang AQ, Zeng W, Chen L, et al. Automated online extraction and tandem mass spectrometry for the analysis of compound I in human plasma [abstract]. Presented at: 15th Annual Symposium of Pharmaceutical and Biomedical Analysis (PBA); May 6, 2004; Florence, Italy
   Google Scholar
• Zeng W, Fisher AL, Musson DG, et al. High-throughput liquid chromatography for drug analysis in biological fluids: investigation of extraction column life. J Chromatogr B Analyt Technol Biomed Life Sci 2004;806:177–83
   PubMed Web of Science ®Google Scholar
• Wei L, Zhang J, Larson P. Analysing pharmacokinetic drug interaction or comparability studies with missing values in crossover designs. Pharm Stat 2003;2:5–14
   Google Scholar
• Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721–49
   Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359–71
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005;22: 255–9
   Google Scholar
• Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741–4
   PubMed Web of Science ®Google Scholar